A protein-sulfosalicylic acid/boswellic acids @metal-organic framework nanocomposite as anticancer drug delivery system

  • Colloids Surf B Biointerfaces. 2021 Aug;204:111788. doi: 10.1016/j.colsurfb.2021.111788.
Münteha Özsoy  1 ,  Vesen Atiroğlu  2 ,  Gamze Guney Eskiler  3 ,  Atheer Atiroğlu  4 ,  Asuman Deveci Ozkan  3 ,  Mahmut Özacar  5
Affiliations
  • 1. Sakarya University, Science & Arts Faculty, Department of Chemistry, 54187, Sakarya, Turkey.
  • 2. Sakarya University, Biomedical, Magnetic and Semiconductor Materials Application and Research Center (BIMAS-RC), 54187, Sakarya, Turkey. Electronic address: [email protected].
  • 3. Sakarya University, Faculty of Medicine, Department of Medical Biology, 54290, Sakarya, Turkey.
  • 4. Sakarya University, Biomedical, Magnetic and Semiconductor Materials Application and Research Center (BIMAS-RC), 54187, Sakarya, Turkey.
  • 5. Sakarya University, Science & Arts Faculty, Department of Chemistry, 54187, Sakarya, Turkey. Electronic address: [email protected].
PMID: 33932885 DOI: 10.1016/j.colsurfb.2021.111788
Abstract

The metal-organic frameworks (MOF) have shown fascinating possibilities in biomedical applications, designing a multifunctional drug delivery system based on the MOF is important. In this study, 5-sulfosalicylic acid and boswellic acids (BAs) were loaded to the pH sensitive zeolitic imidazolate framework-8 (ZIF-8) nanocomposite containing bovine serum albumin (BSA) as the center. The ZIF layer acts as a capsule for the nontoxic storage of 5-sulfosalicylic acid and boswellic acids (BAs) under physiological conditions. The results of the characterization demonstrated the performance of the nanocarrier formation. The pH-sensitive drug release of 5-sulfosalicylic acid was detected due to the innate pH-dependent stability of ZIF-8. An effective pH-sensitive drug delivery system using a 5-sulfosalicylic acid/BSA@ZIF-8, and 5-sulfosalicylic acid/BSA/BAs@ZIF-8, in which the 5-sulfosalicylicacid is not free in physiological pH but it is released at acidic pH (5.0) has been fabricated. The best biocompatibility has been found in 5-sulfosalicylic acid/BSA/BAs@ZIF-8 comparing to the 5-sulfosalicylic acid/BSA, 5-sulfosalicylic acid /BSA/BAs, and 5-sulfosalicylic acid/BSA@ZIF-8. Additionally, 5-sulfosalicylic acid/BSA /BAs@ZIF-8 exhibited higher effectiveness than Other compounds against the breast Cancer cell line, MCF-7, with less toxicity. It is concluded from the results of the current study that the fabricated ZIF-8 based nanocarrier may potentially provide therapeutic effects on breast Cancer cells.

Keywords
5-Sulfosalicylic acid; Boswellic acid; Breast cancer; Drug delivery; ZIF-8.
Products